Brodalumab: A Comprehensive Guide for Patients

What is Brodalumab?

Brodalumab is a medication used to treat certain skin conditions. It's also known by its brand name Siliq¹. Brodalumab is a type of drug called a monoclonal antibody, which is a laboratory-made protein that mimics the immune system's ability to fight off harmful antigens such as viruses. Specifically, it's a human monoclonal IgG2κ antibody that targets a part of the immune system called interleukin-17 receptor A (IL-17RA)².

What Conditions Does Brodalumab Treat?

Brodalumab is primarily used to treat the following conditions:

• Psoriasis: This is a chronic autoimmune condition that causes rapid buildup of skin cells, resulting in scaling on the skin's surface³.
• Hidradenitis Suppurativa (HS): Also known as acne inversa, this is a chronic skin condition characterized by painful, swollen bumps that usually appear in areas where skin rubs together, such as the armpits, groin, and under the breasts⁴.

How Does Brodalumab Work?

Brodalumab works by blocking a specific part of the immune system called interleukin-17 receptor A (IL-17RA). In conditions like psoriasis and hidradenitis suppurativa, the immune system is overactive, leading to inflammation and skin symptoms. By blocking IL-17RA, Brodalumab helps to reduce this inflammation and improve skin symptoms².

How is Brodalumab Administered?

Brodalumab is administered as a subcutaneous injection, which means it's injected just under the skin. The typical dosing schedule is as follows:

• For psoriasis: 210 mg injected at weeks 0, 1, and 2, followed by 210 mg every 2 weeks thereafter³.
• For hidradenitis suppurativa: 210 mg injected at weeks 0, 1, and 2, followed by 210 mg every week for up to 24 weeks in some studies⁵.

It's important to note that the medication should not be injected into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by the condition being treated⁵.

Efficacy of Brodalumab

Clinical trials have shown promising results for Brodalumab in treating both psoriasis and hidradenitis suppurativa:

• For Psoriasis: Studies have used measures such as the Psoriasis Area and Severity Index (PASI) and the static Physician's Global Assessment (sPGA) to evaluate efficacy. A significant number of patients achieved clear or almost clear skin (sPGA score of 0 or 1) after 16 weeks of treatment³.
• For Hidradenitis Suppurativa: Efficacy is often measured using the Hidradenitis Suppurativa Clinical Response (HiSCR), which is defined as a 50% reduction in the total number of abscesses and inflammatory nodules, with no increase in abscesses or draining fistulas. Studies have shown promising results at 16 and 24 weeks of treatment⁵.

Safety and Side Effects

As with all medications, Brodalumab can cause side effects. Common side effects may include:

• Headache
• Joint pain
• Fatigue
• Diarrhea
• Throat pain
• Nausea
• Muscle pain

More serious side effects, although rare, can include increased risk of infections and suicidal thoughts or behaviors. It's important to discuss all potential risks and benefits with your healthcare provider³⁵.

Ongoing Research

Research on Brodalumab is ongoing, particularly in its use for hidradenitis suppurativa. Some current studies are exploring:

• Alternative dosing schedules for hidradenitis suppurativa⁴.
• The effectiveness of Brodalumab in patients who have failed other biologic therapies¹.
• Potential biomarkers that could predict response to treatment⁴.

These ongoing studies aim to further understand the drug's efficacy, safety, and optimal use in different patient populations.

References

[ { "id": "ref1", "order": "1", "url": "https://clinicaltrials.gov/study/NCT04979520" }, { "id": "ref2", "order": "2", "url": "https://clinicaltrials.gov/study/NCT04149587" }, { "id": "ref3", "order": "3", "url": "https://clinicaltrials.gov/study/NCT03403036" }, { "id": "ref4", "order": "4", "url": "https://clinicaltrials.gov/study/NCT04249713" }, { "id": "ref5", "order": "5", "url": "https://clinicaltrials.gov/study/NCT03910803" } ]